Search Results
Your search for ,wAs matches 27470 pages
Showing 17401 - 17450Blinatumomab ‘Takes a BiTE’ Out of Acute Lymphoblastic Leukemia
An investigational immunotherapy is improving outcomes in difficult-to-treat acute lymphoblastic leukemia (ALL) and showing promise in other cancers, as well. Blinatumomab (Blincyto), the first U.S. Food and Drug Administration (FDA)-approved bispecific T-cell engager (BiTE), has demonstrated...
ELCC 2017: Ensartinib Demonstrates CNS Activity in ALK-Positive NSCLC
Ensartinib demonstrated intracranial responses in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, according to findings presented by Reckamp et al at the 2017 European Lung Cancer Conference (ELCC)...
Immune System Is Shaping the Future of Multiple Myeloma Treatment
From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, said Amrita Krishnan, MD, FACP, is figuring out how to incorporate them all, particularly in the...
Social Media: A Knowledge-Sharing Tool in Oncology
Social media is a uniquely positioned platform that can spread specific knowledge to a larger audience. Unlike traditional media, it allows anyone to join the conversation, and according to the Pew Research Center, it is here to stay, with 79% of online American adults using Facebook and 24% using...
QOPI® Certification Program Certifies First Practice in Brazil
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) was the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in...
ELCC 2017: Development and Validation of Lung Toxicity Prediction Models Aids Effective Use of Radiotherapy in NSCLC
Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for delta toxicity endpoints, according to results reported by Defraene et al at the 2017 European Lung ...
Donor Spotlight: Conquering Cancer With Kelly Cares Foundation
Kelly Cares Foundation recently became one of the newest supporters of the Conquer Cancer Foundation of ASCO Young Investigator Awards, the flagship program begun in 1984 to support early-career cancer researchers. The mission of Kelly Cares Foundation is to inspire hope by investing resources to...
Neoadjuvant Immunotherapy in High-Risk Melanoma: A New Approach
Melanoma is an immunogenic tumor, as it expresses various melanoma-specific antigens. However, it is both biologically and clinically heterogeneous. Biologically, it expresses different melanoma antigens and has diverse genetic profiles among different patients. Clinically, it varies in the amount ...
Prognostic and Predictive Effects of TP53 With KRAS or EGFR Mutation Status in NSCLC
In a pooled analysis of four trials of platinum adjuvant therapy vs observation in resected early-stage non–small cell lung cancer (NSCLC), Shepherd et al found no prognostic effect of KRAS or EGFR with TP53 comutation but a potential negative predictive effect for adjuvant therapy with TP53...
Final, 10-Year Follow-up of Phase III Trial on Adding Gemcitabine to Adjuvant Therapy in Breast Cancer
The final, 10-year follow-up of the ‘all comers’ tAnGo trial, reported by Earl et al in The Lancet Oncology, continued to show no overall benefit of adding gemcitabine to adjuvant therapy in women with early-stage breast cancer. The trial, initiated in 2001, included patients...
Karmanos Cancer Institute Now Offers Image-Fusion Technology to Detect Prostate Cancer
The Barbara Ann Karmanos Cancer Institute is using a sophisticated new way to diagnose and treat prostate cancer more effectively. Urology specialists at Karmanos have begun using the UroNav Fusion Biopsy System, which fuses three-dimensional MRI (magnetic resonance imaging) images of the prostate...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in various types of high-grade, aggressive non-Hodgkin lymphomas (NHLs), including peripheral T-cell lymphomas, central...
Expert Point of View: Kelly M. McMasters, MD, PhD
“More and more, we are finding that traditional anatomic TNM staging has significant limitations in predicting prognosis, especially in such cases where response to therapy is an important consideration,” commented session moderator Kelly M. McMasters, MD, PhD, a surgical oncologist at the...
Neo-Bioscore Improves Staging of Breast Cancer Treated With Neoadjuvant Chemotherapy
A new score that incorporates tumor biology and response outperforms conventional histopathologic criteria for the staging of breast cancer treated with neoadjuvant chemotherapy, finds a retrospective validation cohort study.1 Investigators led by John R. Bergquist, MD, MS, MA, a general surgery...
Expert Point of View: Daniel G. Coit, MD
“While these results are clearly superior to historical controls, the study prompts a number of questions,” session moderator, Daniel G. Coit, MD, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, commented in an interview. “Nearly half of the patients received systemic ...
Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases
Hyperthermic intraperitoneal chemoperfusion is efficacious when used as part of multimodality therapy for low-volume peritoneal metastases of gastric cancer, suggests a prospective single-arm phase II trial.1 Among the 19 patients enrolled, all of whom had stage IV disease with either...
Five-Year Survival Quadrupled in Responders to Immunotherapy for Non–Small Cell Lung Cancer
At 5 years, the overall survival rate was 16% in patients with advanced non–small cell lung cancer (NSCLC) treated with single-agent nivolumab (Opdivo), according to follow-up of a phase Ib dose-ranging study (CA209-003), presented at the American Association for Cancer Research (AACR) Annual...
Nivolumab/Ipilimumab Combination Improves Survival Over Ipilimumab Alone in Patients With Melanoma
The race is on to identify combinations of immune checkpoint inhibitors that can improve outcomes over the use of immune checkpoint inhibitor monotherapy. Updated results of the phase III CheckMate 067 trial found the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved survival in...
On the Variance of Cancer Outcomes by Time and Geography
A recent study by Mokdad and colleagues, reviewed in this issue of The ASCO Post, looks at cancer demographic data for 28 cancers and compares mortality rates in 1980 to results in 2014.1 Publishing mortality rates by geographic area and the observation of significant differences is not new. The...
ELCC 2017: Study Shows White Blood Cell–Boosting Drugs Safe During Small Cell Lung Cancer Chemoradiotherapy
A late-breaking subanalysis of the phase III CONVERT trial presented by Gomes et al at the 2017 European Lung Cancer Conference (ELCC) shows that white blood cell–boosting drugs are safe during concurrent chemoradiotherapy of small cell lung cancer (SCLC, Abstract LBA2_PR). “The...
ELCC 2017: Some Patients With Lung Cancer Benefit From Immunotherapy Even After Disease Progression
Some patients with advanced lung cancer benefit from immunotherapy, even after the disease has progressed as evaluated by standard criteria, according to research presented by Artal-Cortes et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 96PD). The findings pave the way for certain ...
ELCC 2017: White Blood Cell Count May Predict Response to Lung Cancer Immunotherapy
White blood cell counts may predict whether patients with lung cancer will benefit from immunotherapy, according to research presented by Tiseo et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 30PD). “Immune checkpoint inhibitors such as nivolumab [Opdivo] and...
ELCC 2017: Osimertinib Improves Symptoms in Advanced Lung Cancer
Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented by Lee et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 85O). “With my...
Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Chen et al, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) is highly active in patients with relapsed or refractory classical Hodgkin lymphoma. Findings in the study ...
IMPAKT 2017: Few Variations in Somatic Mutations Observed Between Pregnant and Nonpregnant Patients With Breast Cancer
Findings comparing the mutational landscape in pregnant and nonpregnant patients with breast cancer that sought to define whether the disease may have a different biology in pregnant women were reported by Loibl et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract...
IMPAKT 2017: Luminal Androgen Receptor Subtype of Triple-Negative Breast Cancer Demonstrates Sensitivity to CDK4/6 Inhibition
Researchers have identified a subtype of triple-negative breast cancer that may be responsive to inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), according to findings presented by Asghar et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract 44P). This study also...
IMPAKT 2017: High Baseline Tumor-Infiltrating Lymphocyte Levels Signal Superior Responses in HER2-Positive Breast Cancer
Baseline levels of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsies from patients with HER2-positive breast cancer are significantly associated with pathologic complete response rates following neoadjuvant chemotherapy plus anti-HER2 agents (trastuzumab [Herceptin], lapatinib...
ASCO Provisional Clinical Opinion: Second-Line Hormonal Therapy for Chemotherapy-Naive Castration-Resistant Prostate Cancer
As reported by Katherine S. Virgo, PhD, MBA, of Emory University, and colleagues in the Journal of Clinical Oncology, ASCO has issued a provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer. The provisional clinical opinion applies...
Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Kurian et al, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics counselor and that many with BRCA1/2 variants of uncertain significance...
AANS 2017: Seizure Outcome After Surgical Resection of Insular Glioma
Winner of the Journal of Neuro-Oncology Award sponsored by Kluwer Academic Publishers, Doris Du Wang, MD, PhD, a resident in the Department of Neurological Surgery at the University of California San Francisco (UCSF), presented her research on seizure outcome after surgical resection of insular...
AANS 2017: Genetic Underpinnings of Desmoplastic Infantile Ganglioglioma/Astrocytoma
Winner of the American Brain Tumor Association Young Investigator Award Anthony C. Wang, MD, a neurosurgeon at the University of California Los Angeles (UCLA) Mattel Children’s Hospital and the David Geffen School of Medicine at UCLA, presented his research findings on desmoplastic infantile...
New Spanish-Language Videos and Brochures From ASTRO Provide an Overview of Radiation Therapy
Spanish-speaking patients with cancer have new tools to help them understand treatment options for their disease. The American Society for Radiation Oncology (ASTRO) has released a series of Spanish-language patient videos on radiation therapy for cancer, including breast, prostate, lung, brain,...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Skinner et al, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous cell carcinoma is sensitive to radiation, HPV-negative tumors are...
Tumor CD274 (PD-L1) Expression and Survival With Aspirin Use in Colorectal Cancer
According to a study reported by Hamada et al in the Journal of Clinical Oncology, postdiagnosis aspirin use was associated with improved survival vs nonuse among patients with colorectal cancer who have lower, but not higher, tumor levels of CD274 (programmed cell death 1 ligand 1; PD-L1). Study...
Adding Bevacizumab to Paclitaxel-Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer
In a phase III trial (NRG Oncology/Gynecologic Oncology Group GOG-0213 trial) reported in The Lancet Oncology, Coleman et al found evidence of an overall survival advantage with the addition of bevacizumab (Avastin) to paclitaxel-carboplatin in recurrent platinum-sensitive ovarian cancer. The...
Cancer Mortality Trends in the United States Vary Widely by County From 1980 to 2014
In a study reported in JAMA, Ali H. Mokdad, PhD, and colleagues from the University of Washington, Seattle, found that cancer mortality rates in the United States dropped from 240.2 to 192.0 per 100,000 population between 1980 and 2014.1 Mortality rates varied widely among U.S. counties for...
Expert Point of View: George Demetri, MD
“I am intrigued by this study. I have no idea by which molecular mechanism this [tumor-treating fields therapy] works, but the data are the data,” said George Demetri, MD, of Dana-Farber Cancer Center, Boston. Dr. Demetri moderated the press conference where these data were discussed. “A panoply...
‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma
Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with...
First-in-Human Experience With Abemaciclib
The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.1 Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...
CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...
CDK4/6 Inhibitors: Their Role in Breast Cancer
The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...
Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...
Genomic Intratumor Heterogeneity and Evolution of NSCLC Tumors
In a study reported in The New England Journal of Medicine, Jamal-Hanjani et al found that early stage non–small cell lung cancer (NSCLC) tumors were characterized by widespread intratumor genomic heterogeneity and that increased subclonal copy-number alterations in this context were...
Long-Term Follow-up of German Hodgkin Study Group Trials in Early-Stage Hodgkin Lymphoma
In an article in the Journal of Clinical Oncology, Sasse et al reported long-term follow-up of German Hodgkin Study Group trials in early-stage favorable and unfavorable Hodgkin lymphoma. The updates cover the HD7 and HD10 trials in favorable disease and the HD8 and HD11 trials in unfavorable...
ELCC 2017: Men May Need More Frequent Lung Cancer Screening Than Women
Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task Force recommends annual screening for lung cancer with low-dose computed tomography (CT) in adults...
Children Conceived After Fertility Treatments May Be at Increased Risk for Pediatric Cancers
Researchers at Ben-Gurion University of the Negev have found that babies born to mothers who underwent fertility treatments may be at increased risk of developing types of pediatric malignancies and neoplasms. The study, published by Wainstock et al in the American Journal of Obstetrics &...
European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing on or After Platinum-Based Therapy
On April 28, the European Commission approved nivolumab (Opdivo) as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology treatment that has...
ASCO/CCO Clinical Practice Guideline Update: Adjuvant Therapy for Resected Non–Small Cell Lung Cancers
As reported in the Journal of Clinical Oncology by Mark G. Kris, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO and Cancer Care Ontario (CCO) have issued an update to the ASCO/CCO clinical practice guideline on adjuvant systemic therapy and adjuvant radiation therapy for stage...
Perioperative Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases
A propensity score analysis in a prospectively maintained database at Memorial Sloan Kettering Cancer Center (MSKCC) has shown that use of perioperative hepatic arterial infusion pump chemotherapy after complete resection of colorectal liver metastases is associated with a marked improvement in...
FDA Approves Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease...
